ABSTRACT
The market for controlled and sustained release delivery forms is well established. Apart form the obvious applications for drugs with short halflives and narrow therapeutic windows, sophisticated delivery systems open up the path for development of drugs with less than ideal physicochemical properties and allow better treatment of diseases which display chronobiology, e.g., rheumatoid arthritis and asthma.
